Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town

OBJECTIVE:Familial hypercholesterolemia (FH) is characterized by elevated low-density lipoprotein-cholesterol and markedly increased cardiovascular risk. In patients with a genetic diagnosis, low-density lipoprotein receptor (LDLR) mutations account for >90% of cases, apolipoprotein B (APOB) muta...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Arteriosclerosis, thrombosis, and vascular biology thrombosis, and vascular biology, 2021-02, Vol.41 (2), p.934-943
Hauptverfasser: Huijgen, Roeland, Blom, Dirk J., Hartgers, Merel L., Chemello, Kévin, Benito-Vicente, Asier, Uribe, Kepa B., Behardien, Zorena, Blackhurst, Dee M., Brice, Brigitte C., Defesche, Joep C., de Jong, Annemiek G., Jooste, Rosemary J., Solomon, Gabriele A.E., Wolmarans, Karen H., Hovingh, G. Kees, Martin, Cesar, Lambert, Gilles, Marais, A. David
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:OBJECTIVE:Familial hypercholesterolemia (FH) is characterized by elevated low-density lipoprotein-cholesterol and markedly increased cardiovascular risk. In patients with a genetic diagnosis, low-density lipoprotein receptor (LDLR) mutations account for >90% of cases, apolipoprotein B (APOB) mutations for ≈5% of cases, while proprotein convertase subtilisin kexin type 9 (PCSK9) gain of function mutations are rare (T) was found in 5 index patients and cascade screening identified 15 additional carriers. Low-density lipoprotein-cholesterol levels were higher in these 15 carriers compared with the 27 noncarriers (236±73 versus 124±35 mg/dL; P
ISSN:1079-5642
1524-4636
DOI:10.1161/ATVBAHA.120.314482